(S)-3,4-methylenedioxyethylamphetamine

(S)-3,4-methylenedioxyethylamphetamine, commonly known as (S)-MDEA or (S)-Eve, is the (S)-enantiomer of the entactogenic drug MDEA. It is a substituted phenethylamine and a member of the amphetamine class. Mechanistically, it acts as a monoamine releasing agent, primarily increasing the synaptic concentrations of serotonin, norepinephrine, and to a lesser extent, dopamine. Compared to its (R)-enantiomer, the (S)-isomer is generally more potent in its effects on serotonin release and is considered the more psychoactive component of the racemic mixture. It was studied in the late 20th century, notably by Alexander Shulgin, but is not approved for any medical indication and is classified as a Schedule I controlled substance in many jurisdictions due to its potential for abuse and lack of accepted medical use.

Other names

(S)-MDEA(S)-Eve(+)-MDEA(S)-N-ethyl-3,4-methylenedioxyamphetamine(S)-N-ethyl-1-(1,3-benzodioxol-5-yl)propan-2-amine